InspireMD's MGuard Coronary:
This article was originally published in Clinica
Executive Summary
Israeli firm InspireMD has received permission to CE mark its MGuard Coronary stent for the treatment of patients with coronary artery diseases. MGuard Coronary combines a coronary stent with an embolic protection device - an ultra-thin polymer mesh sleeve wrapped around the stent, designed to provide embolic shower protection during and after stenting. The sleeve expands when the stent is deployed without affecting the structure of the stent, and diffuses stent pressure on the vessel wall, and thereby may reduce injury and the likelihood of restenosis. The technology may also provide a drug delivery mechanism for next-generation drug-eluting stents. The Tel Aviv-based company claims it has "already received pre-launch orders valued at over $1.5m."
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.